Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy.
about
ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary studyPredictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of OptionsPolymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic reviewUGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapyThymidylate synthase pharmacogenetics.Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.G>C SNP of thymidylate synthase with respect to colorectal cancer.Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival.Tumor growth rate determines the timing of optimal chronomodulated treatment schedulesAnalysis of polymorphisms and haplotype structure of the human thymidylate synthase genetic region: a tool for pharmacogenetic studiesPharmacogenetic aspects in treatment of colorectal cancer--an update.Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adultsThymidylate synthase expression and prognosis in colorectal cancer: a meta-analysis of colorectal cancer survival data.A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival.Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.Loss of heterozygosity at thymidylate synthase locus in Barrett's metaplasia, dysplasia, and carcinoma sequences.The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers.Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing TherapyFOLFIRIĀ® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphismsA DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach.State of Art of Cancer Pharmacogenomics in Latin American Populations.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsClinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era.Basic principles and technologies for deciphering the genetic map of cancer.Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application.Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancersPharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes.Pharmacogenetics and folate metabolism -- a promising direction.Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma.Integrating pharmacogenomics into drug development.The impact of pharmacogenomics on gastrointestinal cancer therapy.Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer.Pharmacogenetics and pharmacogenomics of anticancer agents.Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.Detection of the G>C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis.Targeted therapy and pharmacogenomic programs.EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.Molecular predictors of treatment and outcome in colorectal cancer.
P2860
Q21260394-36E55018-4C46-4199-B033-09A3AB7AF3A3Q26738655-E4314FE2-2039-4C7F-A4F0-2E46B40DCE43Q26824719-4AF54E29-20E8-4C9D-A988-0084F6B549C1Q27851574-DA043140-680A-4A3C-BAB7-28697D088705Q27863339-BFE4B637-9D72-4D66-AF77-FC4FE583A100Q27863360-E4767A75-59DF-4993-A31D-A2DE2A47AFAAQ27863368-A0DBB823-F678-4307-9D0E-85412D3AD573Q27863385-55C89738-CE75-40A5-A42E-8FA96A8CAF21Q28473259-EE3070EB-D0EF-4C8F-AC2E-65AF78CA8087Q28482151-AA4C430E-F73B-4F62-AC54-D25BF43F44CDQ30336665-E2D87620-E137-438F-90DA-CC7FB3F86A65Q30418988-D550E1D3-BDD9-4B17-95F8-2ACF33F5C98EQ30570866-46D6AC65-A11C-45E0-AADF-6C8485FACCA0Q31080865-64F9DFCC-BA84-44F0-A594-F4A1066A2CA6Q33264666-30F3C95F-1D4A-4DAE-8509-7BD5209316C0Q33337970-39340EC0-8688-49EE-ABA3-762B40705B0CQ33424920-D5B3AA8D-194D-4EF7-9A14-62EB266A31B4Q33449893-33D46C5B-ED47-48CC-A0E1-EA4E6B38C966Q33591937-730B0886-A921-4086-A41D-B8DF7C5EB8CDQ33591943-EE0C8273-7EB1-4C20-9765-B6398CC9BE30Q33616231-ECADB1F8-F71B-4260-9677-7EF60E298843Q33810014-70538F82-5EF8-4F69-AADD-8DE7D663F7CDQ33838298-0F214655-FFDC-4EC5-9DC9-28D124E86C0AQ34008793-922AD5F7-67B9-444D-A9FC-21FCB7AB73CDQ34026161-666AB7A1-5289-4B2B-9C55-56300603DECAQ34074628-CFEA9FC4-7798-49F7-A340-D71ACCE4A02DQ34136250-0643C51A-D079-43A2-9F4C-9AC883DCF368Q34214957-E996F5A6-5528-4427-B363-6A298F968066Q34612932-9C7B9829-FD67-4340-9074-7431B44155E9Q34673321-F2A3A7C7-5CE3-4DB1-9929-E143B293A37BQ34743494-C440DF0A-EB78-4893-8FAF-543B22BF6965Q34775310-7134A7F6-8F2C-4A8A-AD04-10501F675D0DQ34837030-EAD75802-53BB-4888-B43E-B1D32D7E141AQ35000906-36A52E58-FE04-4BF0-B860-9967B4149F1AQ35030489-2CCCFF56-F70A-46E4-9B24-B77E9D19CAA0Q35032865-34D6102B-65DF-4606-8BF6-5C8393E309B0Q35083755-AF83AA9B-99D1-4D24-95F6-B2405BCA24E2Q35097981-768C82C9-FEBF-4BCD-94D1-88C99C783B0FQ35146143-530D66FC-4D09-47D2-B61C-4A8671A9EEC3Q35213576-0F1E4C2B-6798-4057-A5C9-0E6A6C628262
P2860
Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy.
description
2001 nĆ® lÅ«n-bĆ»n
@nan
2001幓ć®č«ę
@ja
2001幓å¦ęÆęē«
@wuu
2001幓å¦ęÆęē«
@zh
2001幓å¦ęÆęē«
@zh-cn
2001幓å¦ęÆęē«
@zh-hans
2001幓å¦ęÆęē«
@zh-my
2001幓å¦ęÆęē«
@zh-sg
2001幓åøč”ęē«
@yue
2001幓åøč”ęē«
@zh-hant
name
Thymidylate synthase gene poly ...... toxicity of 5-FU chemotherapy.
@en
Thymidylate synthase gene poly ...... toxicity of 5-FU chemotherapy.
@nl
type
label
Thymidylate synthase gene poly ...... toxicity of 5-FU chemotherapy.
@en
Thymidylate synthase gene poly ...... toxicity of 5-FU chemotherapy.
@nl
prefLabel
Thymidylate synthase gene poly ...... toxicity of 5-FU chemotherapy.
@en
Thymidylate synthase gene poly ...... toxicity of 5-FU chemotherapy.
@nl
P2093
P2860
P356
P1476
Thymidylate synthase gene poly ...... toxicity of 5-FU chemotherapy.
@en
P2093
Pullarkat ST
Stoehlmacher J
Tsao-Wei D
P2860
P2888
P356
10.1038/SJ.TPJ.6500012
P577
2001-01-01T00:00:00Z